Meet Ishwaria Subbiah, M.D.
Ishwaria M. Subbiah, M.D., M.S.
Department of Palliative, Rehabilitation and Integrative Medicine, Division of Cancer Medicine
About Dr. Subbiah
Cancer remains a disease that disproportionately affects older people. Despite accounting for the greatest proportion of those with cancer, older patients represent a significantly lower proportion of patients included in clinical trials. The care of older adults with cancers calls for a substantial understanding of the intricacies of supportive care and geriatrics, oncology as well as phase I/II clinical trial design. Dr. Subbiah is uniquely qualified for this role, having acquired this essential knowledge through her training at MD Anderson first as a Fellow in the Department of Investigational Cancer Therapeutics (A Phase I Program), then in Medical Oncology in the Division of Cancer Medicine and most recently in Department of Palliative, Rehabilitation, and Integrative Medicine. Dr. Subbiah has a thorough understanding of phase I and II clinical trial design, novel therapeutics including immunotherapy and targeted therapies, fundamentals of medical oncology practice and symptom management. With this robust foundation, she cultivates a clinical practice and research focus on symptom management in all patients with particular emphasis on the older adults.
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Palliative Care and Rehabilitation Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Andrew Sabin Family Foundation Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX
Clinical Interests
In line with her clinical role as a symptom management physician and oncologist in the Department of Palliative Care, Dr. Subbiah is equally committed academically to advancing the evidence base for comprehensive holistic care of persons with advanced cancers and their caregivers. Her research places a particular emphasis on improving clinical trial participation among all patients especially those aged 65 years and above and adolescent/young adults (AYA), two populations who remain underrepresented in clinical trials. This vision includes reassessment of inclusion criteria on clinical trials, development of the ideal patient performance assessment tools, and dissemination of best practices to incorporate Supportive Care and Palliative Care early in the disease course to optimize symptoms prior to consideration of and during clinical trial enrollment.
Education & Training
Degree-Granting Education
| 2018 | Jessie H. Jones Graduate School of Business, Rice University, Houston, TX, USA, Certificate, Health Care Management |
| 2008 | St. George’s University, St. George, GRN, MD, Doctor of Medicine |
| 2005 | Johns Hopkins University, Baltimore, MD, USA, MS, Biotechnology |
| 2004 | Johns Hopkins University, Baltimore, MD, USA, BS, Molecular and Cellular Biology |
Postgraduate Training
| 2018-2019 | Butler-Williams Scholar, National Institutes of Health (NIH), National Institute on Aging (NIA), Bethesda, MD |
| 2015-2016 | Clinical Fellowship, Hospice and Palliative Medicine, University of Texas MD Anderson Cancer Center, Houston, TX |
| 2012-2015 | Clinical Fellowship, Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX |
| 2011-2012 | Clinical Fellowship, Investigational Cancer Therapeutics (A Phase I Program), University of Texas MD Anderson Cancer Center, Houston, TX |
| 2009-2011 | Clinical Residency, Internal Medicine, University of Texas Health Science Center at Houston, Houston, TX |
| 2008-2009 | Clinical Internship, Internal Medicine, Albany Medical Center, Albany, NY |
Board Certifications
| 2016 | American Board of Internal Medicine, Hospice and Palliative Medicine |
| 2015 | American Board of Internal Medicine |
Experience & Service
Administrative Appointments/Responsibilities
Organizational Lead for MD Anderson, Palliative Care Research Cooperative Group (PCRC), Denver, CO, 2019 - Present
Member, Junior Investigator Board, R21/33 CARG Infrastructure Grant, Cancer and Aging Research Group (CARG), Duarte, CA, 2018 - Present
Chair, Patient Survey Governance Committee, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - Present
Member, Older Adult Oncology Clinical Practice Guidelines Committee, National Comprehensive Cancer Network (NCCN), Fort Washington, PA, 2018 - Present
Institutional Committee Activities
Member, Primary Palliative Care Acute Care Team (ACT), Department of Emergency Medicine, 2018 - Present
Member, Graduate Medical Education (GME) Diversity & Disparities Committee, 2017 - Present
Translational Research Judge, The MD Anderson Postdoctoral Association 7th Annual Postdoctoral Science Symposium (APSS), 2017 - Present
Member, Graduate Medical Education (GME) Wellness and Career Sustainability Committee, 2017 - Present
Selection Committee Member, MD Anderson Faculty and Alumni Development Endowed Fellowship Award Committee, 2017 - Present
Alternate Member, MD Anderson Faculty Senate, 2017 - Present
Clinical Research Judge, The 2017 MD Anderson Faculty and Alumni Development Annual Trainee Research Day, 2017 - Present
Member, Conference Planning Committee, 21th Annual Interdisciplinary Conference on Supportive Care, Hospice and Palliative Medicine Conference, 2016 - 2017
Member, Program Education Committee, MD Anderson Hospice and Palliative Medicine Fellowship Program, 2016 - Present
Member, ACGME Program Evaluation Committee, MD Anderson Hospice and Palliative Medicine Fellowship Program, 2016 - Present
Member, Candidate Selection Committee, MD Anderson Hospice and Palliative Medicine Fellowship Program, 2016 - Present
Honors & Awards
| 2019 | Andrew Sabin Family Foundation Fellowship |
| 2017 | Young Investigator Award Finalist, The International Society of Geriatric Oncology (SIOG) |
| 2016 | Conquer Cancer Foundation Merit Award, American Society of Clinical Oncology |
| 2013 | Conquer Cancer Foundation Merit Award, American Society of Clinical Oncology |
| 2013 | AACR-GlaxoSmithKline Outstanding Clinical Scholar Award, American Association for Cancer Research |
| 2013 | Marion D. Edwards Fellowship in Hepatic Oncology, MD Anderson Alumni and Faculty Association |
| 2013 | Extramural Award for Patient-oriented Research Loan Repayment Program, National Institutes of Health (NIH) |
| 2012 | Trainee Excellence Award, MD Anderson Alumni and Faculty Association |
| 2012 | AACR-Warner Fund Scholar-in-Training Award, American Association for Cancer Research |
| 2012 | Finalist, Bristol-Myers Squibb Award, Postgraduate Clinical/Translational Research, MD Anderson Alumni and Faculty Association |
| 2012 | ASCO/AACR Methods in Clinical Trials Workshop, American Society of Clinical Oncology/American Association for Cancer Research |
| 2010 | American College of Gastroenterology Presidential Poster Award, American College of Gastroenterology |
| 2010 | Merit/Travel Award winner for the American Society of Hematology (ASH)/Hemophilia and Thrombosis Research Society (HTRS) Coagulation Disorders Workshop, American Society of Hematology (ASH)/Hemophilia and Thrombosis Research Society (HTRS) |
| 2003 | Beta Beta Beta Honor Society, Johns Hopkins University |
| 2003 | Office of Student Involvement Leadership Award, Johns Hopkins University |
| 2003 | The Chester Wickwire Diversity Award, Johns Hopkins University |
| 2003 | Dean’s List, Johns Hopkins University |
| 2002 | Dean’s List, Johns Hopkins University |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Menta AK, Subbiah IM, Subbiah V. Bringing wearable devices into oncology practice: fitting smart technology in the clinic. Discov Med 26(145):261-270, 2018. PMID: 30695675.
- Subbiah IM, Tang C, Rao A, Falchook GS, Subbiah V, Tsimberidou AM, Karp D, Kurzrock R, Hong DS. Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. Oncotarget 9(48):28842-28848, 2018. e-Pub 2018. PMID: 29989021.
- Sen S, Hess K, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Subbiah IM, Liu H, Khanji R, Huang L, Moorthy S, Karp DD, Tsimberidou A, Meric-Bernstam F, Subbiah V. Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. Br J Cancer 118(6):763-769, 2018. e-Pub 2018. PMID: 29462132.
- Subbiah IM, Tsimberidou A, Subbiah V, Janku F, Roy-Chowdhuri S, Hong DS. Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. Oncoscience 4(5-6):47-56, 2017. e-Pub 2017. PMID: 28781987.
- Subbiah IM, Wheler JJ, Hess KR, Hong DS, Naing A, Fu S, Kurzrock R, Tsimberidou AM. Outcomes of patients 65 years old with advanced cancer treated on phase I trials at MD Anderson Cancer Center. Int J Cancer 140(1):208-215, 2017. e-Pub 2016. PMID: 27599876.
- Heilmann AM, Subbiah V, Wang K, Sun JX, Elvin JA, Chmielecki J, Sherman SI, Murthy R, Busaidy NL, Subbiah I, Yelensky R, Nangia C, Vergilio JA, Khan SA, Erlich RL, Lipson D, Ross JS, Miller VA, Shah MH, Ali SM, Stephens PJ. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Oncology 90(6):339-46, 2016. e-Pub 2016. PMID: 27207748.
- Subbiah IM, Falchook GS, Kaseb AO, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Piha-Paul SA, Akmal O, Janku F, Kurzrock R. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget 6(29):28453-62, 2015. PMID: 26164085.
- Subbiah V, Berry J, Roxas M, Guha-Thakurta N, Subbiah IM, Ali SM, McMahon C, Miller V, Cascone T, Pai S, Tang Z, Heymach JV. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. Lung Cancer 89(1):76-9, 2015. e-Pub 2015. PMID: 25982012.
- Subbiah IM, Lei X, Weinberg JS, Sulman EP, Chavez-MacGregor M, Tripathy D, Gupta R, Varma A, Chouhan J, Guevarra RP, Valero V, Gilbert MR, Gonzalez-Angulo AM. Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. J Clin Oncol 33(20):2239-45, 2015. e-Pub 2015. PMID: 25987700.
- Subbiah V, McMahon C, Patel S, Zinner R, Silva EG, Elvin JA, Subbiah IM, Ohaji C, Ganeshan DM, Anand D, Levenback CF, Berry J, Brennan T, Chmielecki J, Chalmers ZR, Mayfield J, Miller VA, Stephens PJ, Ross JS, Ali SM. STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. J Hematol Oncol 8:66, 2015. e-Pub 2015. PMID: 26062823.
- Subbiah IM, Subbiah V. Exceptional responders: in search of the science behind the miracle cancer cures. Future Oncol 11(1):1-4, 2015. PMID: 25572778.
- Subbiah IM, Blackmon SH, Correa AM, Kee B, Vaporciyan AA, Swisher SG, Eng C. Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma. Oncotarget 5(16):6584-93, 2014. PMID: 25051371.
- Subbiah IM, Gonzalez-Angulo AM. Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future. Curr Treat Options Oncol 15(1):41-54, 2014. PMID: 24323591.
- Subbiah V, Subbiah IM. Killing two birds with one stone: BRAF V600E inhibitor therapy for hairy cell leukemia and Langerhans/dendritic cell sarcoma. Ann Hematol 92(8):1149, 2013. e-Pub 2013. PMID: 23322213.
- Tsimberidou AM, Leick MB, Lim J, Fu S, Wheler J, Piha-Paul SA, Hong D, Falchook GS, Naing A, Subbiah IM, Fortier A, Avritscher R, Kurzrock R. Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. Cancer Chemother Pharmacol 71(2):389-97, 2013. e-Pub 2012. PMID: 23143207.
- Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget 4(1):156-65, 2013. PMID: 23391555.
- Kaseb AO, Shama M, Sahin IH, Nooka A, Hassabo HM, Vauthey JN, Aloia T, Abbruzzese JL, Subbiah IM, Janku F, Curley S, Hassan MM. Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. Oncology 85(4):197-203, 2013. e-Pub 2013. PMID: 24051705.
- Tsimberidou AM, Fu S, Subbiah IM, Naing A, Hong DS, Wen S, Fortier AH, Lim J, Kurzrock R. Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. Hepatogastroenterology 59(116):960-4, 2012. PMID: 22580643.
- Subbiah IM, Lenihan DJ, Tsimberidou AM. Cardiovascular toxicity profiles of vascular-disrupting agents. Oncologist 16(8):1120-30, 2011. e-Pub 2011. PMID: 21742963.
Manuals, Teaching Aids, Other Teaching Publications
- Ishwaria Subbiah. Focused Assessment and Study Tool (FAST): Psychiatry and Cognition Module, 3rd Edition. American Academy of Hospice and Palliative Medicine, 2017.
Editorials
- Subbiah IM. Palliative Care in the Time of Hurricane Harvey. Pallimed, 2017.
- Subbiah IM. Integration of End-of-Life Care into Accountable Care Organization's Quality Measures. J Am Geriatr Soc. PMID: 30969433.
Abstracts
- Huey RW, Aloia TA, Subbiah IM. Organizing governance for clinical implementation of electronic patient reported outcomes. International Consortium for Health Outcomes Measurement 2019 Annual Conference, 2019. e-Pub 2019.
- Subbiah IM. A Comparative Analysis of Participation And Clinical Benefit Among Older Adults Versus Middle Age and AYA Patients on Phase I Clinical Trials with VEGF/VEGFR Inhibitors. MASCC/ISOO Annual Meeting on Supportive Care in Cancer, 2018.
- Subbiah IM, Tang C, Rao A, Subbiah V, Kurzrock R, Hong DS. Call to integrate supportive care and patient reported outcomes in early phase clinical trials: An exploration of adolescent and young adult (AYA) participation on phase I trials of novel anticancer agents. ASCO Palliative and Supportive Care in Oncology Symposium, 2017.
- Subbiah IM, Hess KR, Fujii R, Lui A, Subbiah V, Naing A, Hong DS. Integration of supportive care in immuno-oncology trials: Investigating the incidence and severity of immune-related toxicities among older adults versus mid-age patients on immunotherapy-based phase I clinical trials. ASCO Palliative and Supportive Care in Oncology Symposium, 2017.
- Subbiah IM, Hess KR, Fujii T, Alshawa A, Lui A, Roy S, Khanji R, Subbiah V, Naing A, Hong DS. Immuno-oncology and the elderly: A comparative analysis of participation and toxicities of senior adults aged 65 years and above vs mid age and adolescent/young adult patients on immunotherapy-based phase I clinical trials. J Clin Oncol 35, 2017 (suppl; abstr 10034), 2017. e-Pub 2017.
- Subbiah IM, Tang C, Rao A, Subbiah V, Kurzrock R, Karp D, Hong DS. Clinical benefit rate and participation of patients with advanced cancer on phase I clinical trials: A comparative analysis of senior adults aged 65 years and above versus middle age and AYA patients. J Geriatr Oncol. 7/6S1 (2016) S37–S123, 2016.
- Subbiah IM, Tang C, Rao A, Falchook GS, Subbiah V, Kurzrock R, Karp DD, Hong DS. Participation and response assessment of older adults with advanced cancer treated on phase I trials as compared to middle age and AYA patients: An analysis of 1489 patients. J Clin Oncol 34, 2016 (suppl; abstr 10049), 2016. e-Pub 2016.
- Cascone R, Hess KR, Piha-Paul SA, Hong DS, Subbiah IM, Bhatt R, Fu S, Naing A, Janku F, Karp DD, Meric-Bernstam F, Heymach J, Subbiah V. Safety, toxicity and activity of multi-kinase inhibitor vandetanib in combination with everolimus in advanced solid tumors. J Clin Oncol 34, 2016 (suppl; abstr 9073), 2016. e-Pub 2016.
- Cascone T, Subbiah V, Hess KR, Nelson S, Nilsson MB, Subbiah IM, Ali SM, Carbone DP, Salgia R, Owonikoko TK, Meric-Bernstam F, Doebele RC, Heymach J. Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion. J Clin Oncol 34, 2016 (suppl; abstr 9069), 2016. e-Pub 2016.
- Cascone T, Hess KR, Piha-Paul S, Hong DS, Roxas M, Subbiah IM, Fu S, Naing A, Janku F, Karp D, Sherman SI, Meric-Bernstam F, Heymach JV, Subbiah V. A phase I study of everolimus (mTOR inhibitor) in combination with vandetanib (multikinase inhibitor of VEGFR, EGFR, and RET) in advanced solid tumors including molecularly matched aberrations. Mol Cancer Ther Dec 2015, 14 (12 Supplement 2) LB-C17; DOI: 10.1158/1535-7163.TARG-15-LB-C17, 2015.
- Subbiah IM, Varadhachary G, Tsimberidou AM, Wheler JJ, Subbiah V, Janku F, Roy Chowdhuri S, Zinner R, Hong DS. Impaired cell cycle arrest with concurrent epigenetic deregulation identified through next generation sequencing in patients with advanced carcinoma of unknown primary: Implications for personalized medicine. Cancer Res Aug 2015, 75 (15 Supplement) 604; DOI: 10.1158/1538-7445.AM2015-604, 2015.
- Subbiah IM, Janku F, Tsimberidou AM, Naing A, Subbiah V, Wheler JJ, Zinner R, Eng C, Overman MJ, Kopetz S, Hong DS. Concurrent aberrations in the Wnt, MAPK and PI3K pathways identified through next generation sequencing of relapsed refractory colorectal adenocarcinoma (CRC): Implications for future therapeutic trials. Cancer Res Aug 2015, 75 (15 Supplement) 4263; DOI: 10.1158/1538-7445.AM2015-4263, 2015.
- Subbiah IM, Janku F, Tsimberidou AM, Naing A, Subbiah V, Wheler JJ, Zinner R, Eng C, Overman MJ, Kopetz S, Palmer GS, Hong DS. Next-generation sequencing of advanced, relapsed colorectal adenocarcinoma (CRC) to reveal mutations affecting Wnt, MAPK and PI3K pathway signaling: Emergence of novel combinatorial strategies. J Clin Oncol 33, 2015 (suppl 3; abstr 605), 2015.
- Subbiah IM, Varadhachary G, Palmer G, Tsimberidou AM, Wheler JJ, Subbiah V, Janku F, Chowdhuri SR, Zinner R, Meric-Bernstam F, Hong DS. One size does not fit all: Fingerprinting advanced carcinoma of unknown primary through comprehensive profiling identifies aberrant activation of the PI3K and MAPK signaling cascades in concert with impaired cell cycle arrest. Cancer Res Oct 2014, 74 (19 Supplement) 4700; DOI: 10.1158/1538-7445.AM2014-4700, 2014.
- Bupathi M, Falchook GS, Hong DS, Subbiah IM, Piha-Paul SA, Karp DD, Saigal B, Zinner R, Wheler JJ, Tsimberidou AM, Fu S, Sherman SI, Meric-Bernstam F, Subbiah V. A phase 1 trial of vandetanib (multikinase inhibitor of EGFR, VEGFR, and RET) in combination with everolimus (mTOR inhibitor) in patients with advanced malignancies. J Clin Oncol 32:5s, 2014 (suppl; abstr TPS2639), 2014. e-Pub 2014.
- Subbiah IM, Varadhachary GR, Tsimberidou AM, Wheler JJ, Subbiah V, Falchook GS, Janku F, Zinner R, Roy-Chowdhuri S, Meric-Bernstam F, Hong DS. Next-generation sequencing in carcinoma of unknown primary (CUP) and novel combinatorial strategies in a heterogeneous mutational landscape: Implications for personalized medicine. J Clin Oncol 32, 2014 (suppl; abstr e22154), 2014.
- Dasari A, Phan A, Gupta S, Yeung S, Dong M, Culotta K, Hess K, Chen H, Halperin D, Subbiah IM, Meric-Bernstam F, Yao J. A Phase I Study of the Anti-IGF-1R Monoclonal Antibody (MoAb), IMC-A12 (I) and Everolimus (E) in Well Differentiated Neuroendocrine Tumors (WD NET). J Clin Oncol 32, 2014 (suppl 3; abstr 232), 2014.
- Subbiah IM, Dasari A, Escano M, Dagohoy C, Yao JC. Exploratory analysis of early response signals using targeted therapies for the treatment of advanced carcinoid tumor of the kidney. Proceedings of the 2013 North American Neuroendocrine Tumor Society Neuroendocrine Tumor Symposium. October 2013, 2013.
- Subbiah IM, Wheler JJ, Hess KR, Hong DS, Fu S, Wolff RA, Kurzrock R, Tsimberidou AM. Outcomes of patients ≥ 65 yrs with advanced cancer treated on phase I clinical trials. J Clin Oncol 31, 2013 (suppl; abstr 9544), 2013. e-Pub 2013.
- Subbiah IM, Janku F, Naing A, Fu S, Hong DS, Kaseb AO, Herzog C, Kurzrock R, Wolff RA, Subbiah V. Theranostic profiling of adolescents and young adults (AYA) with advanced fibrolamellar hepatocellular carcinoma identifies aberrant activation of the PI3K/AKT/MTOR signaling cascade. Cancer Res Apr 2013, 73 (8 Supplement) 48; DOI: 10.1158/1538-7445.AM2013-48, 2013.
- Subbiah IM, Blackmon SH, Correa AM, Kee BK, Vaporciyan AA, Swisher S, Eng C. Preoperative chemotherapy prior to pulmonary metastatecomy in patients with prior surgically resected primary colorectal carcinoma. J Clin Oncol 31, 2013 (suppl 4; abstr490), 2013. e-Pub 2013.
- Subbiah IM, Janku F, Tsimberidou AM, Naing A, Kaseb AO, Hong DS, Subbiah V, Hess KR, Akmal O, Falchook GS, Kurzrock R. Characteristics and outcomes of patients with advanced hepatocellular carcinoma treated on phase I trials. J Clin Oncol 31, 2013 (suppl 4; abstr281), 2013.
- Subbiah IM, Subbiah V, Naing A, Fu S, Kaseb AO, Falchook GS, Tan D, Herzog CE, Janku F, Kurzrock R. Targeted therapies in early-phase trials for the treatment of advanced fibrolamellar hepatocellular carcinoma. J Clin Oncol 31, 2013 (suppl 4; abstr232), 2013.
- Subbiah IM, Tsimberidou AM, Naing A, Subbiah V, Kaseb AO, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Janku F, Hess KR, Falchook GS, Kurzrock R. Early-phase trials compared to first- and second-line FDA-approved treatments in patients with advanced gallbladder cancer and cholangiocarcinoma. J Clin Oncol 30, 2012 (suppl; abstr e13020), 2012.
- Subbiah IM, Kurzrock R, Naing A, Piha-Paul S, Falchook GS, Hong DS, Wheler JJ, Fu S, Laday S, Tsimberidou AM. A phase I study of lenalidomide in combination with bevacizumab, sorafenib, temsirolimus, or 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in patients with advanced cancers. Cancer Res Apr 2012, 72 (8 Supplement) 1751; DOI: 10.1158/1538-7445.AM2012-1751, 2012.
- Subbiah IM, Tsimberidou AM, Naing A, Subbiah V, Kaseb AO, Falchook GS, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Janku F, Kurzrock R. Early-phase trials in patients with advanced gallbladder cancer and cholangiocarcinoma: The MD Anderson Clinical Center for Targeted Therapy experience. Cancer Res Apr 2012, 72 (8 Supplement) 2669; DOI: 10.1158/1538-7445.AM2012-2669, 2012.
- Subbiah IM, Subbiah V, Kaseb AO, Janku F, Wheler JJ, Naing A, Fu S, Piha-Paul SA, Hong DS, Falchook GS, Tsimberidou AM, Kurzrock R. Characteristics and outcomes of patients with gallbladder cancer and cholangiocarcinoma referred to a phase I clinic. J Clin Oncol 30, 2012 (suppl 4; abstr 364), 2012.
- Subbiah IM, Cen P, Tanikella R, Bryant KW, Liaw VJ, Fallon MB, Cohen AM. Radioembolization of unresectable primary and secondary hepatic malignancies using yttrium-90: The University of Texas at Houston experience. J Clin Oncol 29: 2011 (suppl 4; abstr 311), 2011.
- Freedland SJ, Luo J, De Marzo AM, Dunn T, Fedor H, Darshan M, Mohan I, Isaacs WB. Gene expression differences between prostate cancers from obese and normal weight men. Cancer Res May 2005, 65 (9 Supplement) 745; DOI:, 2005.
Book Chapters
- Morris V, Subbiah IM, Kopetz S, Eng C. Chapter 21: Colorectal Cancer. In: MD Anderson Manual of Medical Oncology. 3. McGraw Hill Professional: New York, NY USA, 2016.
- Subbiah IM, Eng C, Lou E. The Management of Metastatic Disease. In: Comprehensive Rectal Cancer Care. 1. Pertinax Publishing: United Kingdom, 2015.
Letters to the Editor
- Subbiah IM, Brown RE, Fallon MB. Activation of the mammalian target of rapamycin signaling pathway in hepatocellular carcinoma. Hepatology 52: 1524, 2010.
Grant & Contract Support
| Title: | Personalizing care guided by patient-reported outcomes: A comprehensive multimodal strategy to ease the suffering of patients and caregivers with advanced blood cancers |
| Funding Source: | Gabrielle’s Angel Foundation for Cancer Research |
| Role: | Principal Investigator |